Ziprasidone + Placebo

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Generalized Anxiety Disorder

Conditions

Generalized Anxiety Disorder, Bipolar Disorder

Trial Timeline

Feb 1, 2006 → Nov 1, 2008

NCT ID

NCT00374543

About Ziprasidone + Placebo

Ziprasidone + Placebo is a approved stage product being developed by Pfizer for Generalized Anxiety Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT00374543. Target conditions include Generalized Anxiety Disorder, Bipolar Disorder.

What happened to similar drugs?

6 of 20 similar drugs in Generalized Anxiety Disorder were approved

Approved (6) Terminated (3) Active (12)

❌SatralizumabChugai PharmaceuticalPhase 3

🔄Perampanel + Placebo comparatorEisaiPhase 3

🔄PerampanelEisaiPhase 3

🔄CenobamateOno PharmaceuticalPhase 3

🔄Duloxetine + PlaceboEli LillyPhase 3

✅Duloxetine + PlaceboEli LillyApproved

✅IxekizumabEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03768726	Phase 3	Terminated	Dec 21, 2018	Jul 31, 2020	Bipolar Disorder
NCT01172652	Approved	Completed	Apr 1, 2010	Oct 1, 2011	Bipolar Disorder
NCT00483548	Phase 3	Completed	Oct 1, 2007	Dec 1, 2008	Bipolar Disorder
NCT00374543	Approved	Terminated	Feb 1, 2006	Nov 1, 2008	Generalized Anxiety Disorder
NCT00635921	Phase 2	Completed	Mar 1, 2004	Apr 1, 2006	Borderline Personality Disorder

Competing Products

20 competing products in Generalized Anxiety Disorder

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
Satralizumab	Chugai Pharmaceutical	Phase 3	32
Perampanel	Eisai	Pre-clinical	26
Perampanel + Placebo comparator	Eisai	Phase 3	40
zonisamide	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Cenobamate	Ono Pharmaceutical	Phase 3	47
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Ixekizumab	Eli Lilly	Approved	43
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	43
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Escitalopram	AbbVie	Approved	43
Adalimumab	AbbVie	Phase 3	40